Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Aug 1;118(8):1457-1460.
doi: 10.14309/ajg.0000000000002283. Epub 2023 Apr 11.

The Beneficial Effects of Lactobacillus GG Therapy on Liver and Drinking Assessments in Patients with Moderate Alcohol-Associated Hepatitis

Vatsalya Vatsalya  1   2   3 , Wenke Feng  1   3   4   5 , Maiying Kong  6 , Huirong Hu  6 , Gyongyi Szabo  7   8 , Arthur McCullough  9 , Srinivasan Dasarathy  9 , Laura E Nagy  9 , Svetlana Radaeva  10 , Bruce Barton  7 , Mack Mitchell  11 , Craig J McClain  1   2   3   4   5
Affiliations
Randomized Controlled Trial

The Beneficial Effects of Lactobacillus GG Therapy on Liver and Drinking Assessments in Patients with Moderate Alcohol-Associated Hepatitis

Vatsalya Vatsalya et al. Am J Gastroenterol. .

Abstract

Introduction: We investigated the effect of daily oral Lactobacillus rhamnosus GG (LGG) in reducing liver injury/severity and drinking in patients with alcohol use disorder and moderately severe alcohol-associated hepatitis.

Methods: Forty-six male and female individuals with alcohol use disorder and moderate alcohol-associated hepatitis (12 ≤ model for end-stage liver disease score < 20, aged 21-67 years) received either LGG (n = 24) or placebo (n = 22). Data were collected/assessed at baseline and at 1, 3, and 6 months.

Results: LGG treatment was associated with a significant reduction in liver injury after 1 month. Six months of LGG treatment reduced heavy drinking levels to social or abstinence levels.

Discussion: LGG treatment was associated with an improvement in both liver injury and drinking.

Trial registration: ClinicalTrials.gov NCT01922895.

PubMed Disclaimer

Conflict of interest statement

Disclosures/Conflicts of Interest: All authors declare no conflicts of interest.

Figures

Figure 1:
Figure 1:
Liver Injury. A. Liver disease severity as determined by MELD in patients with moderate alcohol-associated hepatitis (mAH) receiving LGG or placebo at baseline and at 1-month time-period. BL: Baseline, LGG: Lactobacillus GG, 1M: 1-month timeline, PL: Placebo, MELD: Model for End-Stage Liver Disease. B. Liver injury as determined by the AST:ALT ratio in patients with moderate alcohol-associated hepatitis (mAH) receiving LGG or placebo at baseline and at 1-month. BL: Baseline, LGG: Lactobacillus GG, 1M: 1-month, PL: Placebo. AST: Aspartate aminotransferase. ALT: Alanine aminotransferase. Data presented as Mean ± Standard Deviation. Statistical significance was set at p<0.05. *p<0.05; **p<0.01.
Figure 2:
Figure 2:
Drinks per week in patients with moderate alcohol-associated hepatitis (mAH) receiving LGG or placebo at baseline, and at 6-month time-period. BL: Baseline, LGG: Lactobacillus GG, 6M: 6-month timeline, PL: Placebo. Data presented as Mean ± Standard Deviation. Statistical significance was set at p<0.05. ***p<0.001, *p<0.05.
See this image and copyright information in PMC

References

    1. Kirpich IA, et al., Liver injury and endotoxemia in male and female alcohol-dependent individuals admitted to an alcohol treatment program. Alcoholism: Clinical and Experimental Research, 2017. 41(4): p. 747–757. - PMC - PubMed
    1. Szabo G and Lippai D, Converging actions of alcohol on liver and brain immune signaling. International review of neurobiology, 2014. 118: p. 359–380. - PubMed
    1. Schmidt C, Thinking from the Gut. Nature, 2015. 518(7540): p. S12–S14. - PubMed
    1. Crabb DW, et al., Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology, 2020. 71(1): p. 306–333. - PubMed
    1. Szabo G, et al., IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. Hepatology, 2022. - PMC - PubMed

Publication types

Associated data